{"id":54827,"date":"2021-08-06T11:25:43","date_gmt":"2021-08-06T15:25:43","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/?p=54827"},"modified":"2023-06-06T18:14:01","modified_gmt":"2023-06-06T22:14:01","slug":"zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/","title":{"rendered":"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS"},"content":{"rendered":"
\"Joshua-zeidner\"<\/a>
Joshua Zeidner, MD<\/figcaption><\/figure>\n

Joshua F. Zeidner<\/a>, MD, discussed the role hypomethylating agents (HMAs) have played in the treatment of higher-risk myelodysplastic syndrome (MDS) in a recent\u00a0OncLive<\/a>\u00a0report. He shared data that shows promising emerging agents like pevonedistat that can be combined with HMAs to improve outcomes for certain patient subsets.<\/p>\n

\n

\u201cWe really have not had any new agents for patients with higher-risk MDS available [since the advent of HMAs] decades ago. We have all been yearning for novel therapies and combinations that can really improve patient survival and responses to HMAs alone,\u201d Zeidner said in the report. \u201cIt is an evolving area, and I\u2019m very hopeful that not only will we find new combinations that will be effective for MDS, but we will be able to pinpoint which subgroups of patients will be able to respond to different therapies. I hope that we may even have a menu of options available. That way, we can select based on specific genomic factors and other patient characteristics and we will not treat patients with a one-size-fits-all approach, such as azacitidine alone.\u201d<\/p>\n

Read the report<\/a>.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Joshua F. Zeidner, MD, discussed the role hypomethylating agents (HMAs) have played in the treatment of higher-risk myelodysplastic syndrome (MDS) in a recent\u00a0OncLive\u00a0report. He shared data that shows promising emerging agents like pevonedistat that can be combined with HMAs to improve outcomes for certain patient subsets. \u201cWe really have not had any new agents for … Read more<\/a><\/p>\n","protected":false},"author":69419,"featured_media":25878,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,517],"tags":[630],"class_list":["post-54827","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-oncology","tag-630","odd"],"acf":[],"yoast_head":"\nZeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS | Department of Medicine<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS | Department of Medicine\" \/>\n<meta property=\"og:description\" content=\"Joshua F. Zeidner, MD, discussed the role hypomethylating agents (HMAs) have played in the treatment of higher-risk myelodysplastic syndrome (MDS) in a recent\u00a0OncLive\u00a0report. He shared data that shows promising emerging agents like pevonedistat that can be combined with HMAs to improve outcomes for certain patient subsets. \u201cWe really have not had any new agents for … Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Medicine\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UNCDeptMedicine\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-06T15:25:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-06T22:14:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"770\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kim Morris\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:site\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kim Morris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/\"},\"author\":{\"name\":\"Kim Morris\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"headline\":\"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS\",\"datePublished\":\"2021-08-06T15:25:43+00:00\",\"dateModified\":\"2023-06-06T22:14:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/\"},\"wordCount\":204,\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg\",\"keywords\":[\"2021\"],\"articleSection\":[\"News\",\"Oncology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/\",\"name\":\"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS | Department of Medicine\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg\",\"datePublished\":\"2021-08-06T15:25:43+00:00\",\"dateModified\":\"2023-06-06T22:14:01+00:00\",\"author\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg\",\"width\":770,\"height\":1024,\"caption\":\"Joshua Zeidner, MD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/\",\"name\":\"Department of Medicine\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\",\"name\":\"Kim Morris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"caption\":\"Kim Morris\"},\"description\":\"Medicine - Dept of\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS | Department of Medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/","og_locale":"en_US","og_type":"article","og_title":"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS | Department of Medicine","og_description":"Joshua F. Zeidner, MD, discussed the role hypomethylating agents (HMAs) have played in the treatment of higher-risk myelodysplastic syndrome (MDS) in a recent\u00a0OncLive\u00a0report. He shared data that shows promising emerging agents like pevonedistat that can be combined with HMAs to improve outcomes for certain patient subsets. \u201cWe really have not had any new agents for … Read more","og_url":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/","og_site_name":"Department of Medicine","article_publisher":"https:\/\/www.facebook.com\/UNCDeptMedicine","article_published_time":"2021-08-06T15:25:43+00:00","article_modified_time":"2023-06-06T22:14:01+00:00","og_image":[{"width":770,"height":1024,"url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg","type":"image\/jpeg"}],"author":"Kim Morris","twitter_card":"summary_large_image","twitter_creator":"@uncdeptmedicine","twitter_site":"@uncdeptmedicine","twitter_misc":{"Written by":"Kim Morris","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#article","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/"},"author":{"name":"Kim Morris","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"headline":"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS","datePublished":"2021-08-06T15:25:43+00:00","dateModified":"2023-06-06T22:14:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/"},"wordCount":204,"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg","keywords":["2021"],"articleSection":["News","Oncology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/","url":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/","name":"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS | Department of Medicine","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg","datePublished":"2021-08-06T15:25:43+00:00","dateModified":"2023-06-06T22:14:01+00:00","author":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#primaryimage","url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg","contentUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg","width":770,"height":1024,"caption":"Joshua Zeidner, MD"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/zeidner-discusses-pevonedistat-with-promising-partner-potential-for-hmas-in-higher-risk-mds\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/medicine\/"},{"@type":"ListItem","position":2,"name":"Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/medicine\/#website","url":"https:\/\/www.med.unc.edu\/medicine\/","name":"Department of Medicine","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529","name":"Kim Morris","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","caption":"Kim Morris"},"description":"Medicine - Dept of","url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/"}]}},"featured_image":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg","featured_image_medium":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo-226x300.jpg","featured_image_medium_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo-768x1021.jpg","featured_image_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo.jpg","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Joshua-Faculty-Photo-150x150.jpg","featured_image_alt":"Joshua-zeidner","category_details":[{"name":"News","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/news\/"},{"name":"Oncology","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/oncology\/"}],"tag_details":[{"name":"2021","link":"https:\/\/www.med.unc.edu\/medicine\/news\/tag\/2021\/"}],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/54827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/users\/69419"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/comments?post=54827"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/54827\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media\/25878"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media?parent=54827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/categories?post=54827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/tags?post=54827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}